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We report on a case of Waldenström’s macroglobulinemia (WM) treated with splenic re-irradiation. To the best
of our knowledge this has not been reported before. A 69-year-old Asian female patient with WM received a
three-dimensional conformal radiotherapy, with 24 Gy in 12 treatment fractions in the first stage. She tolerated
the treatment well, with a 37% reduction of the monoclonal immunoglobulin, an impalpable spleen, and
improved hematological laboratory tests for 4 months. She was then treated with splenic re-irradiation up to
24 Gy for tumor progression. She showed no evidence of progression one year after re-irradiation, with a 55%
reduction of the monoclonal immunoglobulin. Our experience demonstrates that splenic irradiation is an
effective treatment to control the progression of WM.
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Waldenström’s macroglobulinemia (WM) is a lymphoplas-
macytic lymphoma, characteristic of monoclonal immuno-
globulin M (IgM) production and bone marrow infiltration
[1]. Unfortunately, median survival ranges between 60 and
120 months [2]. Most are symptomatic, such as anemia,
leukopenia, splenomegaly, or hepatomegalanemia, and
therefore require further treatment to control symptoms
[3]. Splenic irradiation (SI) can palliate the pain associated
with hypersplenism. Localized radiation of the spleen has
been most widely accepted in the management of lympho-
proliferative and myeloproliferative disorders [4,5].
However, relatively little has been discussed on the use of SI
in the treatment of WM. We report on a case of splenic
re-irradiation for treatment of WM progression. To the best
of our knowledge this has not been reported before.Case presentation
A 69-year-old Asian female presented with fatigue and loss
of weight (4 kg) in March, 2008. Physical examination
revealed massive splenomegaly (4 cm below the left costal
margin) (Figure 1A), and hydropericardium confirmed by
ultrasound examination and computed tomography (CT).* Correspondence: dryuhuajiang@hotmail.com
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reproduction in any medium, provided the orOn 19th June, 2008, blood tests found hemoglobin, 101 g/
L (110–165 g/L); WBC count, 5.5 × 109/L (4.0–10.0× 109/
L), N 45.0%, L 46.4%; platelet count, 222×109/L (100–
300× 109/L). Quantification of serum immunoglobulins
revealed the following: IgG 9.9 g/L (7–16 g/L); IgA 0.8 g/L
(0.7–4 g/L); IgM 15.8 g/L (0.4–2.3 g/L). Erythrocyte
Sedimentation Rate (ESR) is 105 mm/h. Immunofixation
electrophoresis of serum showed monoclonal IgM of
λ type. Bone marrow aspiration revealed WM. The
chest and skeletal radiologic survey revealed no abnor-
mality. The patient was subsequently commenced on
chlorambucil successively. After the use of chlorambucil,
he showed a 50% reduction of the monoclonal immuno-
globulin, a disappearance of lymphoplasmacytic neoplastic
cells from the bone marrow, and an impalpable spleen.
But she developed persistent profound pancytopenia, and
this was therefore stopped. The patient had been under
surveillance for 5 months, with no further active treat-
ment. Bone marrow aspiration and biopsy were repeated,
which had showed focal hypocellularity without any
abnormal cell infiltration until May 2009. At that time, the
spleen increased to the level of 7 cm below the costal
margin in one month. Further treatment was thalidomide
at a starting dose of 200 mg daily with dose escalation to
400 mg. But within 20 days the patient developed transient
grade 3 leukopenia and neutropenia plus persistent grade
3 anemia, which led to discontinuation. The spleen wastd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Sequential computed tomography scan images at the same level. A, At the diagnosis of the disease (19/06/2008); B, Relapsed after
chlorambucil and thalidomide (25/06/2009); C, Before the first stage of 3D-CRT (12/12/2009); D, Before the second stage of 3D-CRT (22/06/2010);
E, At one month after the second stage of 3D-CRT (17/08/2010); F, At one year after the second stage of 3D-CRT (06/07/2011).
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2009, she received FC combination therapy (fludarabine
50 mg for 5 days plus cyclophosphamide 800 mg for 1 day
intravenously, repeated every 28 days). After one cycle, she
showed a 36% reduction of the monoclonal immunoglobu-
lin. Furthermore, the splenomegaly had decreased from
7 cm to 3 cm, below the costal margin by August 2009.
However, the patient had persistent grade 3 leukopenia
plus persistent grade 3 anemia which lasted for 6 months,
and this was therefore stopped. During this period, the
patient had herpes in crissum and pneumonia. Although
the patient received human granulocyte colony stimulating
factors (hG-CSF) and erythropoietin (EPO) repeatedly,
anemia and leukopenia relapsed soon.
The patient was then referred to SI in December 2009.
At that time, palpable splenomegaly increases to 5 cm
inferior to costal margin (Figure 1C). A three-dimensional
conformal radiation therapy (3D-CRT) plan was designed.
In the first stage, the dose prescribed was 24 Gy in 12
treatment fractions via a Varian 23EX linear accelerator.
Three oblique isocentric photon fields (4°, 103° and 179°)
of beam quality 10-MV were delivered. Mean dose to left
kidney, right kidney were 617 cGy and 264 cGy, respect-
ively. Maximum dose to spinal cord was 716 cGy. The
patient had been completely asymptomatic with impalp-
able spleen, and normal hematological laboratory tests for
4 months. In February 2010, she showed a 37% reduction
of the monoclonal immunoglobulin.
The patient presented complaining of several weeks of
generalized weakness and fatigue with pancytopenia in
June 2010. Quantification of serum immunoglobulins
showed that IgM increased to 8.10 g/L (0.4–2.3 g/L).
Physical examinations demonstrated that the spleen wasimpalpable below the costal margin (Figure 1D). The
patient refused to receive chemotherapy or splenectomy,
so she was treated with splenic re-irradiation. The
second stage consisted of 12 fractions, 2 Gy each, by 5
oblique isocentric photon fields (314°, 3°, 32°, 138°, and
179°) of beam quality 10 MV (Figure 2B). The V18 of
kidneys for the sum plan of the two radiation therapies,
were 23.2% (left) and 0.0% (right). The V10 of kidneys
were 46.3% (left) and 0.0% (right). She tolerated
conformal radiotherapy up to 24 Gy well (Figure 1E). Until
July, 2011, she has shown no evidence of progression after
re-irradiation for one year, with no further treatment
(Figure 1F). In July 2011, IgM decreased to 3.65 g/L
(0.4–2.3 g/L), a 55% reduction of the monoclonal
immunoglobulin as compared with before re-irradiation.
Discussion and Recommendations
In hematological disorders, splenomegaly is often involved
with anemia, leukopenia, as well as thrombocytopenia,
which increase the risks of splenectomy. At this time, SI is
deemed to be another effective treatment of hypersplenism.
However, the effects of SI are usually transient. In chronic
lymphocytic leukemia, massive splenomegaly is proved to
be related to a shorter therapy-free as well as overall
survival [6]. WM progressed in our patient after four
months’ completely asymptomatic. The mean duration of
remission after palliative spleen irradiation reported in
most of the studies was 3 to 6 months, although some
cases showed sustained periods of responses [7]. Takemori
et al. [8] and Cavanna et al. [9] reported two cases of
WM treated with chemotherapy and SI resulting in a tran-
sient remission, while splenectomy achieving a sustained
remission for 6 years and 18 years, respectively.
Figure 2 Transaxial slices representative of isodose distribution of 3D-CRT treatment plan delivered for the whole spleen. A, In the first
stage, isodose curves were produced by 3 oblique isocentric photon fields of beam quality 10-MV; B, In the second stage, isodose curves were
produced by 5 oblique isocentric photon fields of beam quality 10-MV.
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splenectomy, so she was treated with splenic re-irradiation
for WM progression. She tolerated the treatment of
3D-CRT up to 24 Gy well. With overall doses between
4 and 10 Gy in mostly 1-Gy fractions, symptoms of
splenomegaly have been improved in 50–87% of chronic
lymphatic leukaemias patients [5]. Although lower dose
per fraction and lower total dose radiation have been a
standard in the treatment of hematological and myelopro-
liferative-associated splenomegaly, we advocate higher
doses for sustained remission used to patients with WM,
especially those who cannot tolerate operation and
chemotharapy. SI may remain practicable for the elderly
patients, even with total dose of 20 Gy [10]. Re-irradiation
for further symptomatic progression is also carried out in
other diseases. It was regarded that splenic re-irradiation
was feasible without excessive toxicity. We think that our
patient can tolerate re-irradiation up to 24 Gy well, partly
because of the use of 3D-CRT. The common technique of
SI is two parallel opposing anterior-posterior portals
encompassing the whole spleen. The use of 3D-CRT is
especially beneficial for patients treated with re-irradiation
or patients with impaired renal function.
Here, SI reduced spleen size, myelosuppression, as well
as high serum IgM level. Based on previous studies on
spleen function, we propose that several biological mechan-
isms are involved in this effect. Firstly, a direct radiation
causes the death of circulating lymphoplasmacytoid cells in
the spleen. The main radiobiological mechanism of
radiation-induced death is mitotic catastrophe, interphase
death and terminal growth arrest (senescence) [11].
Secondly, given that the spleen contained abundant IgM-
producing lymphocytes, SI impairs the production of mono-
clonal immunoglobulin. Peripheral blood mononuclear cells
are unable to differentiate into immunoglobulin-secreting
cells in splenectomized patients [12]. Thirdly, local radiationinduces the spleen release of several cytokines, such as
TNF-α, INF-γ and IL-2. These cytokines produce an
abscopal effect with immunological responses against
distant tumor cells [13]. At the same time, SI impairs normal
CD8+ T-suppressor cells function [5]. The absence of CD8+
T-suppressor cells enhances anti-tumour response. Fourthly,
high dose of radiation may induce spleen fibrosis, which
may prevent from recurrent splenomegaly [5].
Conclusion
Our experience demonstrates that SI is not only a pallia-
tive treatment to relieve the pain of splenomegaly, but also
an effective treatment to control the progression of WM.
In cases of patients who refuse to have a splenectomy for
recurrent hypersplenism, splenic re-irradiation may be
another treatment. We recommend the use of 3D-CRT in
re-irradiation for better renal protection.
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